Two-year home-based nocturnal noninvasive ventilation added to rehabilitation in chronic obstructive pulmonary disease patients: A randomized controlled trial
2011

Home-based Nighttime Ventilation for COPD Patients

Sample size: 66 publication 10 minutes Evidence: moderate

Author Information

Author(s): Marieke L Duiverman, Johan B Wempe, Gerrie Bladder, Judith M Vonk, Jan G Zijlstra, Huib AM Kerstjens, Peter J Wijkstra

Primary Institution: University Medical Center Groningen, University of Groningen

Hypothesis

Does adding two years of home-based nocturnal noninvasive ventilation (NIPPV) to rehabilitation improve outcomes in COPD patients with chronic hypercapnic respiratory failure?

Conclusion

Adding NIPPV to pulmonary rehabilitation for two years improves health-related quality of life, mood, dyspnea, gas exchange, exercise tolerance, and lung function decline in severe COPD patients.

Supporting Evidence

  • NIPPV improved health-related quality of life as measured by the Maugeri Respiratory Failure questionnaire.
  • Mood state improved significantly in the NIPPV + PR group compared to the PR group.
  • Dyspnea scores showed greater improvement in the NIPPV + PR group.
  • Daytime arterial blood gases improved more in the NIPPV + PR group.
  • Exercise tolerance was maintained in the NIPPV + PR group while it deteriorated in the PR group.
  • FEV1 stabilized in the NIPPV + PR group compared to a decline in the PR group.

Takeaway

This study shows that using a special breathing machine at night can help people with severe lung problems feel better and breathe easier during the day.

Methodology

A randomized controlled trial comparing two groups: one receiving nocturnal NIPPV plus rehabilitation and the other receiving rehabilitation alone, with outcomes assessed over two years.

Potential Biases

Potential bias due to lack of blinding and the small sample size.

Limitations

The study was not blinded, and the sample size was smaller than initially calculated, which may affect the results.

Participant Demographics

{"age_range":"40-76 years","gender_ratio":"M:F 16:8 in NIPPV + PR group; 17:15 in PR group","comorbidities":["osteoporosis","hypertension","cardiac dysfunction","depression","diabetes mellitus"]}

Statistical Information

P-Value

0.005

Confidence Interval

95% CI: -22.7 to -4.2

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1465-9921-12-112

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication